Loading
Ionis Pharmaceuticals Inc Stock: price and insider trades · United States
1 insider bought €923k of shares over the last 90 days, the latest filed 31 Jul 2026.
Ionis Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Ionis Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, the company's managers filed 116 filings, from 31 insiders.
On the market, 1 insider bought (2 purchases totalling €923k) while 15 insiders sold (39 sales totalling €16.5M). The amount is not disclosed for 8 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 senior executive. Monia Brett P filed the largest sale, €2.1M, on 10 February 2026.
With 116 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Since 2016, the database holds 4 purchases and 139 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 943.7 m USD and net income of -381.4 m USD.
The clock since the last published purchase (31 July 2026) now reads 78 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
481
Thresholds
n/a
Buy Volume
€1M
4 ops. · all time
Sell Volume
€29M
139 ops. · all time
Who traded when
BuySaleMonia Brett P9 sales
Joseph Baroldi8 sales
C. Frank Bennett6 sales
Parshall B Lynne6 sales
Swayze Eric5 sales
Wender Joseph H5 sales
+12 other insiders
Since the insiders bought
- -21.0%Entry US$54.49 · Close 16 Oct 2026 US$43.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ionis Pharmaceuticals Inc Buy (bullish), based on 22 analysts. Average price target: US$83.64.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,094 of 24,148 companies
28.3
score / 100
Value22
Quality35
FCF yld-4.6%
Earn yld-5.3%
EV/EBITDA·
ROE-105%
Gross mgn98%
Net mgn-40%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$42.70
Analyst consensus
22 analystsBuy
US$54.00Target US$83.64(+96%)US$105.00
Income statement
RevenueUS$943.7M
Gross profitUS$927.8M98% margin
EBITDA-US$272.6M-29% margin
Net income-US$381.4M-64.7% margin
Valuation
PER (forward)-38.4x
P/Book16.1x
Beta0.38
Balance sheet & cash
Market capUS$7.1B
Total debtUS$2.1B
Free Cash Flow-US$325.7M
Debt / Equity498%
Profitability & ownership
ROE-105.5%
ROA-12.4%
% insiders0.6%
% institutions110.3%
Last declaration on 16 October 2026
Declarations481 total
1,357 shares@ US$44.00Common StockSEC144:0000874015-26-000263
15,000 shares@ US$53.380.011% mcap48.8% of flowCommon StockSEC:0000874015-26-000254:0
Canonical exit: 28 Oct 2026 (T+90)
5,000 shares@ US$51.600.0035% mcap15.6% of flowCommon StockSEC:0000874015-26-000254:1
Canonical exit: 29 Oct 2026 (T+90)
5,220 shares0Common StockSEC:0000874015-26-000244:0
5,220 shares0Common StockSEC:0000874015-26-000245:0
15,000 shares0Common StockSEC:0000874015-26-000239:1
5,536 shares@ US$83.5790.0063% mcap3.7% of flowCommon StockSEC:0000874015-26-000239:0
15,000 shares@ US$85.4620.017% mcap10.1% of flowCommon StockSEC:0000874015-26-000239:2
362 shares@ US$84.300.0004% mcap0.7% of flowCommon StockSEC:0000874015-26-000236:0
10,111 shares@ US$47.110.0065% mcap17.6% of flowCommon StockSEC:0000874015-26-000237:0
10,111 shares@ US$85.41560.012% mcap31.9% of flowCommon StockSEC:0000874015-26-000237:1
67,386 shares@ US$84.95420.078% mcap45.2% of flowCommon StockSEC144:0001972481-26-000225
10,111 shares@ US$85.41560.012% mcap31.9% of flowCommon StockSEC144:0001972481-26-000227
1,287 shares@ US$84.29990.0015% mcap2.4% of flowCommon StockSEC144:0001972481-26-000226
11,518 shares@ US$39.940.0063% mcap7.8% of flowCommon StockSEC:0000874015-26-000229:0
99 shares@ US$79.450.0001% mcap0.1% of flowCommon StockSEC:0000874015-26-000229:1
11,419 shares@ US$79.03940.012% mcap15.2% of flowCommon StockSEC:0000874015-26-000229:2
11,518 shares@ US$79.0430.012% mcap15.4% of flowCommon StockSEC144:0001972481-26-000222
3,866 sharesCommon StockSEC:0000874015-26-000218:0
1,769 sharesCommon StockSEC:0000874015-26-000218:1
5,635 sharesCommon StockSEC:0000874015-26-000218:2
26,000 sharesCommon StockSEC:0000874015-26-000216:0
26,000 sharesCommon StockSEC:0000874015-26-000216:1
3,069 sharesCommon StockSEC:0000874015-26-000217:0
5,635 shares@ US$80.15950.0047% mcap100.0% of flowCommon StockSEC144:0001972481-26-000215
25 of 481 declarations
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. (ticker: IONS) is a U.S.-listed biopharmaceutical company traded on the Nasdaq in the United States. Headquartered in Carlsbad, California, and founded in 1989, Ionis is widely regarded as one of the pioneers of antisense technology and RNA-targeted medicines. Its business model now combines an emerging wholly owned commercial platform with a substantial base of partnered programs and royalty revenue, giving the company a distinctive profile in the mid-cap biotechnology universe.
Ionis built its reputation by advancing oligonucleotide-based therapeutics for genetically driven and otherwise hard-to-treat diseases. The company’s core scientific edge is its proprietary RNA-targeted drug discovery platform, which is designed to modulate disease-causing proteins by acting upstream at the RNA level. This platform has produced a deep pipeline and a track record of important regulatory and commercial firsts. Ionis now markets several medicines directly or through partners, including TRYNGOLZA (olezarsen), approved for familial chylomicronemia syndrome; DAWNZERA (donidalorsen), approved for hereditary angioedema prophylaxis; and WAINUA (eplontersen), approved for hereditary transthyretin-mediated amyloidosis with polyneuropathy. It also receives royalties from partnered products such as SPINRAZA and QALSODY, both commercialized by Biogen. In addition, older assets such as TEGSEDI and WAYLIVRA remain available in selected international markets.
Read moreShow less
From a competitive standpoint, Ionis occupies a differentiated niche at the intersection of rare disease, neurology, cardiovascular risk, and RNA therapeutics. Its competitive moat is not scale in the traditional pharma sense, but rather scientific depth, platform leadership, and a growing ability to translate research assets into commercial franchises. For investors, the company increasingly looks like a transition story: from a long-duration R&D organization into a more integrated commercial-stage biotech with a more visible earnings trajectory.
Geographically, the United States remains the company’s most important market, but Ionis also has approved products and commercial arrangements across Europe, Canada, and other regions through partners. Recent catalysts have been meaningful. In 2026, Ionis highlighted strong momentum from the U.S. launches of TRYNGOLZA and DAWNZERA, while also advancing late-stage and regulatory programs such as zilganersen for Alexander disease and the potential broader commercialization of olezarsen in severe hypertriglyceridemia. The company has also emphasized improving financial momentum, supported by product sales, royalties, and collaboration revenue, which is important for investors assessing the durability of its growth story.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
